The U.S. Food and Drug Administration (FDA) has cleared the Medtronic In.Pact AV drug-coated balloon (DCB) for the treatment of failing arteriovenous (AV) access in patients with end-stage renal...
Drug-Eluting Balloons
This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.
-
-
November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs.
-
Royal Philips introduced two new balloons to its Stellarex 0.035-inch low-dose drug-coated balloon (DCB) portfolio. The new 200mm and 150mm Stellarex 0.035-inch low-dose DCBs have received...
-
October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no statistically significant mortality increase.
News | November 26, 2019
November 21, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic In.Pact AV drug-coated...
The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of the Medtronic IN.PACT AV Access drug-coated balloon (DCB) met both of its endpoints, in data presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting.
News | Drug-Eluting Balloons | November 14, 2019
November 7, 2019 — The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of...
The In.Pact Admiral drug-coated balloon.
News | Drug-Eluting Balloons | November 07, 2019
November 7, 2019 — Real-world, four-year study results of the In.Pact Admiral drug-coated balloon (DCB) demonstrate...
The AngioDynamics/Eximo Medical B-Laser atherectomy system.
News | Atherectomy Devices | November 07, 2019
November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs. plain old balloon angioplasty (...
News | Drug-Eluting Balloons | November 06, 2019
November 6, 2019 – Positive, two-year data from the first-in-human study of Selution SLR, MedAlliance’s novel...
News | Peripheral Artery Disease (PAD) | November 06, 2019
November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-...
News | Drug-Eluting Balloons | October 15, 2019
October 15, 2019 — Royal Philips introduced two new balloons to its Stellarex 0.035-inch low-dose...
News | Drug-Eluting Balloons | October 10, 2019
October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no...
Videos | TCT | October 04, 2019
News | Drug-Eluting Balloons | September 20, 2019
September 20, 2019 — Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured...
News | Peripheral Artery Disease (PAD) | August 27, 2019
August 27, 2019 — Concept Medical was recently granted Breakthrough Therapy designation by the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | August 14, 2019
August 14, 2019 — Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food...
News | Drug-Eluting Balloons | August 02, 2019
August 2, 2019 — B. Braun Interventional Systems Inc. (BIS) announced the U.S. Food and Drug Administration (FDA)...
News | Drug-Eluting Balloons | June 13, 2019
June 13, 2019 — Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for...
News | Drug-Eluting Balloons | May 29, 2019
May 29, 2019 — Philips announced the three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE...
